Ledyard Financial Gr (LFGP) 47.2500 $LFGP Ledyard Named

New Post Public Reply Private Reply Replies (0) Message Board
Stock_Tracker
Ledyard Financial Gr (LFGP) 47.2500 $LFGP

Ledyard Named One of Top 200 Community Banks
BusinessWire - Tue May 17, 9:26AM CDT
Ledyard Financial Group, Inc. (Ticker Symbol: LFGP), the holding company for Ledyard National Bank, was ranked among the Top 200 publicly traded banks and thrifts in the United States by American Banker Magazine. The rankings were based on return on average equity across three years. Ledyard Financial Group ranked 159th with a three-year average ROAE of 9.33%.

Ledyard Financial Group Reports Quarterly Earnings
BusinessWire - Wed May 04, 2:17PM CDT
Ledyard Financial Group, Inc. (ticker symbol LFGP), the holding company for Ledyard National Bank, today reported quarterly earnings for the first quarter of 2016. Net income for the quarter ended March 31, 2016, was $1,005,045 or $0.98 per share compared to $1,119,680 or $1.10 per share for the same period in 2015, a decrease of $114,635 or 10%. The decrease in net income for the quarter is due primarily to the decline in revenue at Ledyard Financial Advisors, which was caused by a decline in assets under management during the quarter, due to volatility in the equity markets. Additionally, interest income was higher in 2015 due to a recovery of interest on a problem loan.

Ledyard Financial Group Declares Quarterly Dividend
BusinessWire - Fri Jan 29, 11:17AM CST
Ledyard Financial Group (Ticker Symbol: LFGP) announced today a regular quarterly dividend of $0.48 per share, to be paid March 4, 2016 to shareholders of record as of February 12, 2016.

Ledyard Financial announces dividend of USD0.48 per share for quarter
M2 - Mon Nov 02, 8:15AM CST
Ledyard Financial Group (Other OTC:LFGP) declared on Friday that it will paya regular quarterly dividend of USD0.48 per share.

Ledyard Financial announces USD0.48 per share quarterly dividend
M2 - Mon Aug 03, 6:11AM CDT
Ledyard Financial Group (Other OTC:LFGP) on Saturday declared a regular quarterly dividend of USD0.48 per share.

Ledyard Financial Group Declares Increase to Quarterly Dividend
BusinessWire - Fri Jan 30, 1:56PM CST
Ledyard Financial Group (Ticker Symbol: LFGP) announced today a $0.03 increase to its quarterly dividend. The dividend of $0.48 is payable March 3, 2015 to shareholders of record as of February 13, 2015. The dividend was last increased by $0.04 for the dividend paid during September 2014. Strength in the Company's core businesses is supporting the ability to continue with its dividend payouts and ensure that its shareholders benefit from the Company's improved earnings.

Robert Wetzel Joins Ledyard National Bank Board of Directors
BusinessWire - Thu Jan 29, 9:45AM CST
Ledyard Financial Group (Ticker symbol: LFGP) is pleased to announce that Robert O. Wetzel has joined its Board of Directors.

Ledyard Financial Group Reports Financial Results for the Third Quarter
BusinessWire - Tue Oct 28, 9:22AM CDT
Ledyard Financial Group, Inc. (ticker symbol LFGP), the holding company for Ledyard National Bank, today reported its financial results for the third quarter of 2014. Net income for the quarter ended September 30, 2014, was $1,069,538 or $1.05 per share compared to $770,834 or $0.76 per share for the same period in 2013, an increase of $298,704 or 38.8%. Net income for the nine months ended September 30, 2014 was $2,995,493, or $2.95 per share compared to $2,324,331 or $2.30 per share for the same period in 2013, an increase of $671,162 or 28.9%. The increase in net income for the quarter and first nine months when compared to the prior year is due to an increase in lending activity and an increase in revenue from Ledyard Financial Advisors.

Scroll down for more posts ▼

Top 10 Most Recent News Articles

Johnson & Johnson's JNJ-6143 Shines in Prostate Cancer Study

Updated Category News Views 145

Prostate Cancer's Persistent Challenge No one in the healthcare game needs the reminder: prostate cancer is no walk in the park, especially for those grappling with advanced stages. Now picture this—you're on your sixth treatment, and the cloud is not lifting. It's a battle that never ends, with traditional therapies sometimes barely holding the line. JNJ-6143's New...

Continue Reading
Swanson Nexus Pro Launch: Boost for Dietitians

Updated Category News Views 213

Swanson Enters the Education Arena for Nutritionists Swanson Vitamins is mixing things up again! This time, they're launching something called Swanson Vitamins Nexus Pro, aimed squarely at the registered dietitians and licensed nutritionists crowd. Starting out as the place to grab your basic vitamins, Swanson's not resting on their supplement laurels. No, siree. They've...

Continue Reading
CapCut's Role in AI-Assisted Small Biz Marketing

Updated Category News Views 25

In today's fast-paced digital world, small businesses lament the constant hustle to stay relevant online. This juggling act with limited resources often makes effective marketing feel like a high-wire circus performance. Enter AI tools, promising to lighten the load, and CapCut stands out as a game-changer. AI Tools Revolutionizing Small Business Marketing Amid growing...

Continue Reading
Innovent's IBI354: New Data Spurs Hope for HER2+ BC

Updated Category News Views 106

Innovent Lauds HER2 ADC's Moment at ESMO 2026 Alright, chin up, investors. At the 2026 ESMO Congress, Innovent's throwing down some promising Phase 2 data for their brainchild, IBI354. You hear that name and it's like hearing about a rock star in the making in the oncology world. The potential here isn’t just talk—it's a loud, resounding call for attention. Their...

Continue Reading
ASTS Faces Crucial Deadline Amidst Legal Turmoil

Updated Category News Views 208

Ah, the ticking clock in the world of stock investments, where a nifty little thing called a class action lawsuit can flip your investment on its head. Right now, AST SpaceMobile (NASDAQ: ASTS) investors are staring down the barrel of one such lawsuit. With the November 13, 2026, deadline looming, it's time to sort the facts from the muck. Pins and Needles for ASTS...

Continue Reading
Master Sommeliers and Italian Producers Clash on Wine Lists

Updated Category News Views 166

Wines Jockeying for New York’s Coveted Lists Alright, picture a stage set up in New York City like an arena. But instead of gladiators, you've got master sommeliers on one side and Italian wine producers on the other, each armed with their own arguments. They're locked in a battle over what it really takes to get a bottle imbedded on a New York City's prestigious wine...

Continue Reading
World Young Scientist Summit 2026 in Wenzhou Kicks Off

Updated Category News Views 231

Young Minds Meet AI Innovation Crack open the playbook, and it's clear: young brains from across the globe are gathering in Wenzhou, Zhejiang, China, to wrangle with AI and chart the course of science toward a sustainable future. The World Young Scientist Summit 2026 isn't just a parade of speeches and accolades. Nah, it's a deep dive into where innovative minds believe...

Continue Reading
Wenda Pharma's NHWD-870 HCl Shows Promise in Trial

Updated Category News Views 266

Breaking Through in NUT Carcinoma Treatment Imagine battling an aggressive disease with barely any options left, and then something hopeful shows up in the pipeline. That's the story with Zhejiang Wenda Pharma's NHWD-870 HCl, an oral BET inhibitor making waves at the 2026 ESMO Annual Meeting. Facing off against the nasty beast that is NUT carcinoma, this drug didn't just...

Continue Reading
CSTS Unveils PremierX in NYC: A Bold Entertainment Move

Updated Category News Views 270

Welcome to the New Era of Entertainment Out of the blockbusters and into the open air, eh? On October 30, 2026, CSTS Enterprises flipped the New York skyline into a canvas for their grand kickoff of PremierXTM—a live entertainment brand poised to redefine how we gobble up our music, sport, and art. Now, there's a shot of adrenaline New Yorkers weren't exactly begging...

Continue Reading
Kelun-Biotech's Sacituzumab Tirumotecan Shows Promise in NSCLC

Updated Category News Views 48

Kelun-Biotech's Recent Breakthrough Grab your coffee, and let's chat about something that might just change the lung cancer treatment game: Kelun-Biotech's sacituzumab tirumotecan, or sac-TMT, showing some serious promise in a Phase III trial. With numbers that could make any investor sit up a little straighter, this study has turned heads at the European Society for...

Continue Reading

Top 5 Most Recently Viewed Articles

Discover How Indovinya's Innovations Boost Sustainable Agriculture

Updated Category News Views 93

Unlocking the Potential of Biopesticides in Agriculture Indovinya introduces innovative solutions to enhance the use of biologically based products amidst a growing drive for sustainable crop protection. Advancements in Biopesticide Utilization The adoption of biopesticides as an alternative to traditional agrochemicals is gaining traction. However, the integration of...

Continue Reading
SCHMID Group Expands Influence with New Equipment Orders

Updated Category News Views 155

SCHMID Group Strengthens Market Position with New Orders In an exciting development from the SCHMID Group, a key player in the equipment manufacturing sector, the company has recently secured significant orders for Panel Level Packaging (PLP) and modified Semi-Additive (mSAP) production equipment. The orders mark a noteworthy advance as SCHMID continues to bolster its...

Continue Reading
X4 Pharmaceuticals Completes Major Equity Financing and Leadership Shift

Updated Category News Views 178

Major Equity Financing by X4 Pharmaceuticals X4 Pharmaceuticals has made headlines recently with its announcement of a significant private equity financing round totaling $60 million. This funding is primarily geared towards advancing the company’s promising treatment for rare immune system diseases, demonstrating their commitment to improving patient outcomes. Leading...

Continue Reading
IGI Secures Fast Track from FDA for Promising Cancer Treatment

Updated Category News Views 124

IGI Receives Fast Track Designation for ISB 2001 Results from the dose-escalation portion of the Phase 1 clinical study of ISB 2001, an innovative treatment for heavily pretreated multiple myeloma patients, will be showcased at an upcoming major oncology conference. This exciting news highlights IGI's continued progress in developing groundbreaking therapies. About ISB...

Continue Reading
Prospera Energy Reports Strong Financial Performance for 2024

Updated Category News Views 163

Prospera Energy's Transformative Year: A Deep Dive into 2024 Financial Results In the recent strategic realignment, Prospera Energy Inc. (TSX.V: PEI, OTC: GXRFF) has successfully pivoted under new leadership, making significant strides in enhancing its production capabilities and financial outlook. This transformation was marked by key appointments, including Shubham Garg...

Continue Reading